Skip to main content
Sunesis extends dose-escalation study timeline for vecabrutinib

Sunesis Pharmaceuticals has extended the timeline for its vecabrutinib dose-escalation study, which is evaluating the drug for adults with chronic lymphocytic leukemia and other B cell cancers. Sunesis will also increase the number of patients in the 50-mg group to six after one participant experienced adverse events and another patient's disease progressed, with results from the Phase Ib study expected to be ready this fall, according to interim CEO Dayton Misfeldt.

Full Story: